Get Free Consultation

Email Us:  support@cspanresearchsol.com

Head Office +91 8729085230

Guru Angad Nagar,
New Delhi 110092

09.00 to 18.00 Monday to Saturday

Industry Detail
  • Home
  • Industry Detail

Market Introduction:

The Global Digital Biomarkers Market is expected to offer an $ opportunity value of USD 81,899.50 Million over the projected period.

The global market was estimated around USD 2,315.2 million during the base year i.e. 2022, and expected to touch USD 84,214.7 million through the ending period 2035. The significant growth is expected in the market during the forecast period.

Base Year2022
Forecast Year2024-2035
CAGR33.65%
Base Year Market Size (2022)USD 2,315.2 Million
Forecast Year Market Size (2035)USD 84,214.7 Million

The acceleration in the growth of the market can be deciphered through the market lenses, the rising prevalence of majority of chronic disorders. Most of the chronic disorders are slow growing and is demanding the fast predictable diagnosis. The Change is disease pathophysiology, diagnosis tools must be enhanced to the level, so it can detect any disease at earliest.

Moreover, in addition to these developments, factors that are attributable to surge the growth of digital biomarkers market is developments and advancement in digital health technology integration. Incorporation of digital technologies in healthcare space is having tremendous impact in every aspect of healthcare field.

Report Insights on Impact of Digital Biomarkers in Treatment Landscape: 

  • Digital biomarkers continue to assist researchers and other healthcare stakeholders to enhance its usage for the advancements of future medicine. As disease pathophysiology is changing rapidly owing to significant change in peoples life style leading to the demand of precision medicines
  • Measurements of behavioural and physiological data are the key parameters for developments of targeted medicines
  • Digital biomarkers can increase the diagnostic and therapeutic precision in the modern health care system by remotely and continuously measuring reliable clinical data and allowing continuous evaluation and monitoring
  • Data captured by wearable, implantable, and digestible devices and sensors technologies, digital biomarkers can be used at home to provide a clinical data, collecting data that is not feasible in the clinical setting

  • Digital Biomarkers covers the clinical activities such as Fitbit devices, activity trackers, and implantable cardiac defibrillators
  • In the last few years, several technologies companies are focusing on the developments of digital devices. Today market is full of these types of devices available to track the physiological health parameters. In the last couple of years, Fitbit, Jawbone, Apple Health, Withings, Garmin, Sleep as Android, WIWE, MocaCare, Skeeper – in other terms, fitness trackers, step counters, health apps, sleep sensors, pocket ECG, blood pressure or other health parameter measuring devices. 

Report Strategic Insights:

  • Nearly 75% of United States population is willing to adopt the wearable technologies and this is expected to rise further in the future
  • FDA refers a digital biomarker to be a characteristic or set of characteristics, collected from digital health technologies, that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions
  • Asia-Pacific is expected to lead the adoption in future. As various country government is emphasizing on the digital technology adoption

Growth Enablers: Explored in the Report

  • Rising Adoption of Remote Sensing Technologies: The technological driven devices enable professionals to figure out patients and retrieve their medical records more quickly. Remote sensing and monitoring technologies permit healthcare providers to obtain timely information about a patient's vital signs without needing to schedule an in-person visit.
  • Growing Use of Biomarkers for Identifying Neurological Disorder
  • The integration of digital devices and digital biomarkers into clinical trials is an important driver of health research digitalization
  • Rising Development of Drug Delivery Method

Challenges: Explored in the Report

  • Interoperability of Digital Biomarkers is Missing in the Space
  • Privacy and Security Related Challenges Associated with Digital Biomarker 
  • Error in Response Measurements

Regional Market Outlook:

  • The North America Market is projected to reach USD 38,453.6 million over the analysis period 2035.  United States currently is the largest market driving the entire region. As the people are getting more health conscious the adoption of digital solution getting huge attention. Chronic disease prevalence is on higher side in the country and rising spending on health is also taking larger interest in the country.

  • Europe Market Overview: Reimbursement approval of biomarker tests typically not linked to (or in time with) medicine reimbursement. Cancer represents the second largest cause of death and morbidity in Europe, with more than 3.7 million new cases and 1.9 million deaths each year. 
  • In the United Kingdom and Danish country, all biomarker testing (including single biomarker and NGS) is centralised to regional or national levels
  • In France, all molecular diagnostic testing is centralised to the regional reference laboratory network, ensuring that hospitals lacking in-house capabilities also have access to testing via referral pathways
  • In Germany, a national programme (nNGM Lungenkrebs) offers NGS testing for lung cancer patients via a network of 15 university cancer centres.
  • Changing market dynamics are creating avenues in the emerging markets. Growing healthcare expenditure, rising awareness, recognition of technological driven world among others are the factors creating conducive environment for digital health world. Asia-Pacific market is creating mix situation for as younger and older people are rising in the region are enough reasons for digital potential market. 

Market Segmentation:

Our in-depth analysis of the global Digital Biomarkers Market includes the following segments:

Global Digital Biomarkers Market
Base Year:2022Forecast Period:2024-2035
Historical Data:2022Market Size in 2022:USD 2,315.2 Million
Forecast Period 2024-35 CAGR:33.65%Market Size in 2035:USD 84,214.7 Million
Segments Covered:By Component

 

  • Data Collection Tools
    • Mobile Apps
    • Wearables
    • Biosensors
    • Contact-Free Sensors
  • Data Integration Systems
By Therapeutic Area
  • Cardiovascular Diseases
  • Neurodegenerative Disorders
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Alzheimer’s Disease
  • Sleep and Movement Diseases
  • Chronic Pain
  • Gastrointestinal Diseases
  • Diabetes
  • Respiratory Conditions
By Application
  • Wellness
  • Disease Diagnosis
  • Personalized Medication
  • Drug Discovery and Development
By Region
  • North America (U.S., Canada)
  • Europe (United Kingdom, Germany, France, Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, South Korea, Rest of APAC)
  • Middle East & Africa (Saudi Arabia, Israel, UAE, South Africa, Rest of MEA)
  • South America (Brazil, Mexico, Argentina, Rest of South America)
Key Market Drivers:
  • The integration of digital devices and digital biomarkers into clinical trials is an important driver of health research digitalization
  • Rising Adoption of Remote Sensing Technologies
Key Market Restraints:
  • Regulatory challenges
Key Trends:
  • Adoption of smart devices
  • Players with highly advanced solutions
Companies Covered in the Report:
  • BrainScope
  • Machine Medicine
  • Medable. Private Company
  • Empatica Inc.
  • Aural Analytics
  • nQ Medical
  • IMVARIA Inc.
  • ALTOIDA
  • ActiGraph, LLC.
  • VivoSense
  • EVOCAL Health GmbH
  • Koneksa Health
  • Cosinuss GmbH
  • Biofourmis
  • Lunit Inc.
  • Other Major Players

Recent Developments in the Market:

  • June 2023: Koneska Health joined hands with Beacon Biosignals, a biomarker platform engineered firm in the United States that is designed to speed up clinical trials and facilitate novel medications for patients with neurological and psychiatric diseases, to conduct clinical trials
  • April 2023: ActiGraph formed the collaboration with Precision Digital Health (PDH), a United States based company that provides wearable and biomarker data solutions.

Place An Order

Related Reports